{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:14:56Z","timestamp":1794953696393,"version":"4.9.1"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune suppression, exhaustion, and senescence are frequently seen throughout disease progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg i.v. on day 14 to examine whether PD-1 inhibition improves clinical responses in relapsed\/refractory (R\/R) AML. Overall responders could receive pembrolizumab maintenance up to 2 years. Among 37 patients enrolled, the overall response rate, composite complete remission (CRc) rate (primary endpoint), and median overall survival (OS) were 46%, 38%, and 11.1 months, respectively. Patients with refractory\/early relapse and those receiving treatment as first salvage had encouraging outcomes (median OS, 13.2 and 11.3 months, respectively). Grade \u22653 immune-related adverse events were rare (14%) and self-limiting. Patients who achieved CRc had a higher frequency of progenitor exhausted CD8+ T cells expressing TCF-1 in the bone marrow prior to treatment. A multifaceted correlative approach of genomic, transcriptomic, and immunophenotypic profiling offers insights on molecular correlates of response and resistance to pembrolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R\/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage regimen. Further study of pembrolizumab and other immune-checkpoint blockade strategies after cytotoxic chemotherapy is warranted in AML.<\/jats:p>\n                    <jats:p>See related commentary by Wei et al., p. 551.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 549<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-21-0070","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T11:35:12Z","timestamp":1631273712000},"page":"616-629","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed\/Refractory Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"first","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-2282","authenticated-orcid":false,"given":"Benjamin G.","family":"Vincent","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."},{"name":"3University of North Carolina, Department of Microbiology and Immunology, Chapel Hill, North Carolina."},{"name":"4Program in Computational Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[{"name":"5University of North Carolina School of Medicine, Department of Biostatistics, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Moore","sequence":"additional","affiliation":[{"name":"5University of North Carolina School of Medicine, Department of Biostatistics, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen P.","family":"McKinnon","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"3University of North Carolina, Department of Microbiology and Immunology, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec D.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupkatha","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mazziotta","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"7University of Siena, Department of Medical Biotechnologies, Siena, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna A.","family":"Knaus","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-3838","authenticated-orcid":false,"given":"Matthew C.","family":"Foster","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Jamieson","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Van Deventer","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Webster","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"8Department of Oncology, Division of Hematological Malignancies, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle T.","family":"Prince","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"8Department of Oncology, Division of Hematological Malignancies, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"8Department of Oncology, Division of Hematological Malignancies, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-7390","authenticated-orcid":false,"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"8Department of Oncology, Division of Hematological Malignancies, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"8Department of Oncology, Division of Hematological Malignancies, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"9Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"8Department of Oncology, Division of Hematological Malignancies, Johns Hopkins School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Serody","sequence":"additional","affiliation":[{"name":"1University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina."},{"name":"2Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina."},{"name":"3University of North Carolina, Department of Microbiology and Immunology, Chapel Hill, North Carolina."},{"name":"4Program in Computational Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-3412","authenticated-orcid":false,"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"6Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."},{"name":"7University of Siena, Department of Medical Biotechnologies, Siena, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"2022060217164563300_bib1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"2022060217164563300_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060217164563300_bib3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"2022060217164563300_bib4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060217164563300_bib5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022060217164563300_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajh.25333","article-title":"A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease","volume":"94","author":"Litzow","year":"2019","journal-title":"Am J Hematol"},{"key":"2022060217164563300_bib7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060217164563300_bib8","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.clml.2020.06.007","article-title":"Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia","volume":"20","author":"Ravandi","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022060217164563300_bib9","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"key":"2022060217164563300_bib10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood-2010-04-277939","article-title":"Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells","volume":"117","author":"Kanakry","year":"2011","journal-title":"Blood"},{"key":"2022060217164563300_bib11","doi-asserted-by":"crossref","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"2022060217164563300_bib12","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"key":"2022060217164563300_bib13","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2022060217164563300_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"key":"2022060217164563300_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur J Haematol"},{"key":"2022060217164563300_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/eji.201242814","article-title":"Myeloid leukemia cells with a B7\u20132(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands","volume":"43","author":"Dolen","year":"2013","journal-title":"Eur J Immunol"},{"key":"2022060217164563300_bib17","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"2022060217164563300_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2022060217164563300_bib19","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060217164563300_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"2022060217164563300_bib21","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"key":"2022060217164563300_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"2022060217164563300_bib23","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","article-title":"Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans","volume":"21","author":"Galletti","year":"2020","journal-title":"Nat Immunol"},{"key":"2022060217164563300_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+) tumor-infiltrating T cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"key":"2022060217164563300_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"2022060217164563300_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022060217164563300_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","article-title":"Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"2022060217164563300_bib28","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1158\/1078-0432.CCR-18-3886","article-title":"A phase I\/II trial of MEC (mitoxantrone, etoposide, cytarabine) in combination with ixazomib for relapsed refractory acute myeloid leukemia","volume":"25","author":"Advani","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022060217164563300_bib29","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060217164563300_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0145-2126(99)00087-9","article-title":"A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study","volume":"23","author":"Karanes","year":"1999","journal-title":"Leuk Res"},{"key":"2022060217164563300_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1365-2141.2003.04336.x","article-title":"Mechanism of action of purine analogues in chronic lymphocytic leukaemia","volume":"121","author":"Pettitt","year":"2003","journal-title":"Br J Haematol"},{"key":"2022060217164563300_bib32","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.3324\/haematol.2015.130013","article-title":"Empiric definition of eligibility criteria for clinical trials in relapsed\/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON\/SAKK and SWOG","volume":"100","author":"Walter","year":"2015","journal-title":"Haematologica"},{"key":"2022060217164563300_bib33","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"2022060217164563300_bib34","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","article-title":"A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia","volume":"88","author":"Estey","year":"1996","journal-title":"Blood"},{"key":"2022060217164563300_bib35","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"2022060217164563300_bib36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"2022060217164563300_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"2022060217164563300_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","article-title":"Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2022060217164563300_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"2022060217164563300_bib40","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","article-title":"Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression","volume":"25","author":"Xu","year":"2014","journal-title":"Cancer Cell"},{"key":"2022060217164563300_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"2022060217164563300_bib42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2010-01-262543","article-title":"Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"116","author":"Becker","year":"2010","journal-title":"Blood"},{"key":"2022060217164563300_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2014-07-591461","article-title":"Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways","volume":"125","author":"Gr\u00f6schel","year":"2015","journal-title":"Blood"},{"key":"2022060217164563300_bib44","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"2022060217164563300_bib45","article-title":"The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results [abstract]","volume-title":"Proceedings of the 62nd ASH Annual Meeting and Exposition; 2020 Dec 5\u20138","author":"Sallman","year":"2020"},{"key":"2022060217164563300_bib46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"key":"2022060217164563300_bib47","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol"},{"key":"2022060217164563300_bib48","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"key":"2022060217164563300_bib49","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022060217164563300_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"2022060217164563300_bib51","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res"},{"key":"2022060217164563300_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s42003-019-0415-5","article-title":"diffcyt: differential discovery in high-dimensional cytometry via high-resolution clustering","volume":"2","author":"Weber","year":"2019","journal-title":"Commun Biol"},{"key":"2022060217164563300_bib53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/2\/6\/616\/3098997\/616.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/2\/6\/616\/3098997\/616.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:32:24Z","timestamp":1654176744000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/2\/6\/616\/665895\/Phase-II-Trial-of-Pembrolizumab-after-High-Dose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,10]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0070","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.6550243.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22543396","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550243","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22543396.v1","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}